After a two-month pilot program in which Vali reduced the delivery time of cytogenetic clinical analysis by 50% using their cutting-edge AI technology, the company signed a significant agreement with Eurofins Spain, a subsidiary of the French laboratory group Eurofins Scientific SE.

Rodrigo Nielsen, Vali’s CSO and co-founder, explained that, in addition to reducing delivery times, they also managed to clear the backlog of pending studies in Spain, further demonstrating the efficacy of Vali’s technology.

The success of this pilot coincided with another major milestone for the company: achieving CE Marking, which validates that their processes comply with European safety regulations.

“Having this endorsement, along with the agreement with Eurofins Spain, opens doors for us to expand into other European subsidiaries of the laboratory conglomerate. Our plan is to target Europe, while also working towards obtaining FDA validation to enter the U.S. market,” Nielsen stated.

He added, “This agreement allows us to realize our solution’s full potential. We have always known our capability to provide fully automated responses in tight deadlines, but the pilot and now the agreement give us invaluable experience. This will enable us to grow in many aspects, from our business model to scaling up, and even exploring other areas where we can offer precise solutions and make a greater impact.”